Vivantes Netzwerk fuer Gesundheit GmbH

At Vivantes Netzwerk fuer Gesundheit GmbH, the cardiovascular program focuses on atrial fibrillation and the prevention of serious cardioembolic events. The studies are designed to assess whether new treatment approaches can better protect patients from stroke and other systemic complications.

• Atrial fibrillation and stroke prevention
• Comparing a new therapy with standard care to reduce cardioembolic risk
• Improving treatment effectiveness for patients with ongoing heart rhythm disorders

These trials aim to strengthen long-term care for people living with cardiovascular disease, with a clear emphasis on preventing major complications and improving clinical outcomes.

The site also supports studies in male urogenital diseases, especially prostate cancer. Research here is centered on patients with recurrent or high-risk disease, with the goal of improving control of cancer that returns after initial treatment.

• Biochemically recurrent prostate cancer
• Evaluating whether a new hormone-based treatment approach can delay disease progression
• Using advanced imaging to better understand treatment benefit

These efforts reflect a strong interest in refining therapy for prostate cancer and identifying strategies that may improve recurrence management and disease monitoring.

Breast cancer is a major area of research at Vivantes Brustzentrum, covering both early and advanced HR-positive, HER2-negative breast cancer. The trials are exploring whether newer treatment combinations can improve survival and reduce the chance of cancer returning or spreading.

• HR-positive, HER2-negative breast cancer
• Locally advanced and metastatic disease
• Testing new treatment combinations to improve progression-free and invasive breast cancer-free survival

This research includes studies of targeted therapy, endocrine therapy, and treatment strategies for patients who have already received prior therapy, with the aim of improving outcomes in a difficult-to-treat cancer setting.

The site is also involved in studies of muscle-invasive bladder cancer, particularly in patients who are eligible for cisplatin-based treatment. This work examines whether adding an immune-based approach around surgery can improve cancer control.

• Cisplatin-eligible muscle-invasive bladder cancer
• Assessing whether treatment before and after surgery can improve event-free survival
• Supporting better outcomes for patients undergoing radical cystectomy

These trials are focused on improving the effectiveness of standard care by testing whether newer combinations can reduce the risk of recurrence and support longer-term disease control.